Condensed Consolidated Statement of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues	$ 33,336	$ 30,150
Cost of revenues	16,588	15,129
Gross profit	16,748	15,021
Operating expenses:
Research and development, net	5,353	5,035
Clinical operations, net	1,601	1,776
Sales and marketing	13,469	21,408
General and administrative	5,364	8,010
Total operating expenses	25,787	36,229
Operating loss	(9,039)	(21,208)
Financial income, net	(424)	(869)
Loss before taxes on income	(8,615)	(20,339)
Taxes on income	143	21
Net loss	$ (8,758)	$ (20,360)
Net loss per share:
Net loss per share: Basic	$ (0.05)	$ (0.13)
Net loss per share: Diluted	$ (0.05)	$ (0.13)
Weighted average number of common shares used in computing basic and diluted net loss per share:
Basic	161,797,781	154,083,443
Diluted	161,797,781	154,083,443